Drug intelligence / Profile preview

BELOTERO Soft Lidocaine

Development stage
Unknown
Lead developer
Merz Aesthetics
Modality
Small Molecules
Administration
Intradermal
01

Overview

BELOTERO Soft Lidocaine is a sterile, viscoelastic, hyaluronic acid-based dermal filler developed by Merz Aesthetics and manufactured by Anteis SA. It is formulated using Cohesive Polydensified Matrix (CPM) and Dynamic Cross-Linking (DXL) technologies, which allow the gel to integrate seamlessly into the skin's dermal layers. The product contains 20 mg/ml of cross-linked sodium hyaluronate of non-animal origin and 0.3% lidocaine hydrochloride, which serves as a local anesthetic to enhance patient comfort during the injection process. It is specifically indicated for the correction of superficial fine lines and wrinkles, such as perioral lines and crow's feet, as well as for deep skin hydration. The gel is typically injected into the superficial to mid-dermis, with aesthetic effects lasting between 6 to 18 months.

Brand names
BELOTERO Soft Lidocaine
Other names
Belotero Soft with LidocaineBelotero Soft + Lidocaine
02

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on BELOTERO Soft Lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BELOTERO Soft Lidocaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call